Bayer seeks double US indications for riociguat: CTEPH, PAH
This article was originally published in Scrip
Executive Summary
Bayer HealthCare is seeking the US FDA's blessing to market riociguat in two indications: persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable diseases – for which it would be the first drug in the US for that condition – and pulmonary arterial hypertension (PAH).